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CORRESPONDENCE
Letters to the Editor
Relationship Between
Noninvasive Coronary
Angiography With Multislice
Computerized Tomography and
Myocardial Perfusion Imaging
In the paper by Schuijf et al. (1), they report findings on
myocardial perfusion imaging (MPI) and multislice computer-
ized tomography (MSCT) in symptomatic patients referred for
MPI. Although the findings were of great interest, we were
concerned with several of the conclusions the authors drew from
them. In a subset of the patients reported (58 of 114) invasive
coronary angiography was performed. Of the 27 patients
demonstrated to have angiographically severe coronary stenosis,
MSCT identified 27 (100%) and MPI identified only 16 (59%).
Of the 31 patients shown not to have severe coronary stenosis,
MSCT identified 25 (82%) and MPI identified 15 (48%). From
these results, the investigators’ conclusion was that “the dis-
crepant results provided by the 2 techniques underscore that
MSCT and MPI provide complementary information.” This
conclusion is surprising, because although the authors offer
reasonable evidence that the 2 techniques yield discrepant
results, they give no evidence that the techniques are comple-
mentary. Because the authors do not offer any prestated
hypothesis, their conclusion seems to be imposed on post hoc
data that showed surprisingly poor efficacy for the current
reference standard noninvasive examination, MPI. Although
other studies have shown a relatively low clinical event rate in
patients with normal MPI exams, it is not known if a benign
prognosis can be generalized to symptomatic patients with
severe coronary artery disease (CAD) demonstrated on angiog-
raphy (2–4).
The authors also state that “patients with an abnormal MSCT
and abnormal MPI should be referred for invasive angiography
with potential revascularization.” This conclusion, too, is not based
on their presented data. The decision to pursue invasive testing is
complex and generally based on the patient’s clinical features. It is
therefore an overly broad conclusion to base this decision solely on
the suggestion of abnormal perfusion seen on MPI. Sequential
testing, which the authors advocate, seems a costly and unnecessary
step.
The accuracy with which MSCT demonstrates the presence and
extent of CAD makes it a welcome addition to the noninvasive
armamentarium. Based on the authors’ findings of frequent dis-
crepant results between these techniques, further investigation is
warranted to test patient outcomes when clinical decisions are
guided by MSCT versus MPI.
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Reply
We thank Drs. Spevack and Levsky for their interest in our article
on the relationship between multislice computed tomography
(MSCT) coronary angiography and myocardial perfusion imaging
(MPI) (1).
In our study, MSCT and MPI were compared in patients with
an intermediate pretest likelihood. In the majority of patients with
normal MSCT (no atherosclerosis), MPI was normal as well.
However, in patients with significant lesions on MSCT, MPI
results were abnormal in only 50%, indicating that MSCT can not
predict abnormal perfusion/ischemia. Nonetheless, these observa-
tions also showed that the presence of substantial atherosclerosis,
including significant stenoses, cannot be ruled out by MPI. Thus,
the techniques may be considered to provide different information;
whereas MPI provides information on the presence of ischemia,
MSCT tells us whether atherosclerosis is present or not. Integra-
tion of both, therefore, may prove helpful in deciding the optimal
treatment strategy.
The first concern that Drs. Spevack and Levsky raise is that our
observations appear to be based on data showing poor efficacy for
MPI. However, their argument is predominantly based on the
findings of a subanalysis of our data, namely, the performance of
MSCT and MPI in those patients referred for conventional
coronary angiography. However, we recommend that those obser-
vations be treated with care, because they are hampered by the
presence of referral bias, thus negatively influencing MPI results in
particular. In our paper, therefore, those data are solely used to
confirm that MSCT has a good diagnostic accuracy in patients at
intermediate risk. Moreover, one needs to realize carefully that
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even obstructive atherosclerotic lesions do not necessarily result in
ischemia. With the increasing awareness of the mismatch between
ischemia (MPI) and atherosclerosis/stenosis (MSCT and invasive
angiography), one may even question the use of lesions on
angiography as the gold standard.
The second issue the authors raise concerns our statement that
in patients with abnormal MPI revascularization may be indicated.
We fully agree with the authors that clinical presentation also
should always be considered when deciding the need for revascu-
larization. Nevertheless, in contrast to the opinion of Drs. Spevack
and Levsky, we feel that assessment of the presence and extent of
ischemia are of paramount importance in the prediction of benefit
from revascularization. Recently, Hachamovitch et al. (2) pub-
lished their observations in 5,366 consecutive patients without
earlier revascularization who received either medical therapy or
revascularization after initial MPI. In line with previous studies
(3), the authors demonstrated that survival benefit from revascu-
larization is proportional to the extent of ischemia. Although left
ventricular ejection fraction was found to predict cardiac death,
only inducible ischemia identified which patients had a short-term
benefit from revascularization.
However, we fully agree with Drs. Spevack and Levsky that
despite normal MPI results long-term outcomes may differ be-
tween patients with either minor or severe coronary artery disease
(CAD). Indeed, the identification of considerable CAD in patients
with still normal MPI may become an important advantage of
using MSCT coronary angiography in addition to MPI. To this
purpose, sequential imaging strategies could potentially be bene-
ficial. Unfortunately at present, available data are too scarce to
support such algorithms. Indeed, we fully agree with the authors
that further investigations addressing patient outcomes as well as
cost-effectiveness are highly warranted.
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Statins and Aortic Stenosis
in the Context of Ratio of
Low- to High-Density
Lipoprotein Cholesterol
In a recent paper by Moura et al. (1), it was found that
lipid-lowering therapy with a statin, namely, rosuvastatin, showed
beneficial effects in slowing the progression of the aortic stenosis.
Aortic stenosis has long been associated with atherosclerosis by
many authors in the context of common risk factors with common
pathophysiologic scenarios (2,3). The lipid hypothesis is one of the
most enthusiastic ones, attracting attention after Otto et al. (2)
showed that aortic valve disease behaved in an almost similar
manner as atherosclerosis on microscopic samples, although there
were some differences, particularly, more influence of calcification.
This enthusiasm brought about a prospective study (4), which
failed to show any beneficial effect on valve disease progression
despite significant decrease in low-density lipoprotein (LDL)
cholesterol with atorvastatin in a group of patients with heavily
calcified aortic stenosis. This issue is also mentioned in the recent
paper (1), and the potential difference is attributed to the difference
in the severity of the aortic disease, which could definitely be
accepted as one of the answers. In addition to this point, in the
paper it was (1) stated that there was a significant correlation (1)
between the LDL decrease, which was almost similar to that in the
earlier study (4), and the progression of the aortic disease, which
was definitely not correlated with LDL cholesterol in the previous
study (4). On the other hand, what is not presented nor mentioned
in either paper is that both statins are known to differ in terms of
their effects on high-density lipoprotein (HDL) cholesterol, and
the LDL to HDL cholesterol ratio (5). In our study (6), we had
shown that there was a significant correlation between the rate of
aortic valve disease progression and the total cholesterol to HDL
cholesterol level ratio, with fast progression occurring in the group
with higher ratios. It is rational within this concept to expect that
better normalization, which has been shown to be significantly
better with rosuvastatin (5), might yield better results. Neither of
the 2 studies (1,4) pointed this out. We think that in addition to
the severity of the aortic valve disease, a delicate balance of lipid
profile with HDL cholesterol behaving in opposition to LDL
cholesterol might have a significant role in aortic stenosis progres-
sion just as in atherosclerosis. However, this issue remains to be
established.
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